Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-FGFR2b/topoisomerase-1 inhibitor antibody-drug conjugate BG-C137

An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the fibroblast growth factor receptor 2b (FGFR2b; fibroblast growth factor receptor 2 isoform IIIb; FGFR2 IIIb) conjugated to an as of yet undisclosed topoisomerase-1 inhibitor, with potential antineoplastic activity. Upon administration of anti-FGFR2b/topoisomerase-1 inhibitor ADC BG-C137, the antibody moiety targets and binds to FGFR2b-expressing tumor cells. Upon binding and internalization, the topoisomerase-1 inhibitor is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing FGFR2b. FGFR2b is overexpressed on certain tumor cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-FGFR2b ADC BG-C137
anti-FGFR2b/Top-1i inhibitor ADC BG-C137
FGFR2b-targeted ADC BG-C137
Code name:BG C137
BG-C137
BGC137
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search